ALGS vs LIN · rev $3.6M vs P/E 34, rev $33.99B
Aligos Therapeutics Inc (ALGS) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Aligos Therapeutics Inc (ALGS) is a biotechnology company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported ALGS revenue for 2024-12-31 was $3.6M. Net income was -$131.2M. Revenue was down 41.7% from 2023-12-31 to 2024-12-31. ALGS currently screens at market cap $44.1M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
ALGS currently screens at market cap $44.1M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the ALGS and LIN stock pages for the full models.
Not investment advice.